By Evelyne Newton, Business Development Europe at Velocity Clinical Research
Next week I will join industry leaders to explore one of the most pressing questions facing sites across Europe: how can clinical trial sites diversify therapeutic areas sustainably without compromising quality?
In a competitive and fast-moving environment, diversification is often framed as a necessary growth strategy. Yet expanding into new indications simply to capture the latest protocol trend is rarely sustainable. Done reactively, it can dilute performance, stretch teams too thin, and weaken a site’s reputation. Done strategically, it builds resilience, strengthens capability, and positions organisations for long-term success.
At Velocity, we believe diversification should reinforce your core strengths, not distract from them.
Strategic expansion begins with data-driven clarity
Entering a new therapeutic area requires discipline. It begins with a clear-eyed assessment of Sponsor pipelines, CRO activity, regulatory approvals, and regional disease burden. It requires honest benchmarking of historical enrolment speed, screen failure rates, investigator capacity, and patient demographics. Most importantly, it demands us not just to ask“Can we do this?” but “Can we do this well and repeatedly?”
As a large, integrated organisation operating across multiple European markets, Velocity aggregates performance data across dozens of sites. This allows us to evaluate readiness with precision and identify where expansion is genuinely viable. Scale, when used intelligently, provides clarity rather than complexity.
Capabilities and talent define the competitive edge
Therapeutic diversification is ultimately a people strategy. No site can expand successfully into a new therapy area without experienced Principal Investigators, targeted therapeutic training, operational depth, and infrastructure readiness.
One of Velocity’s most powerful enablers of growth is our PIVOT programme. Through PIVOT, experienced PIs train and mentor other physicians across the organisation, sharing expertise in a structured and scalable way. Instead of rebuilding capability from scratch with every expansion, we activate the knowledge already present within our network.
This approach accelerates readiness while protecting quality. Cross-leveraged expertise reduces ramp-up risk, strengthens protocol adherence, and builds confidence for sponsors exploring new indications with us. In a large integrated network like Velocity, diversification means unlocking the expertise that already exists rather than starting from scratch.
Supporting newly acquired sites to expand capability
Growth through acquisition is common across Europe, but adding geography alone does not automatically expand therapeutic depth. True expansion only happens when newly acquired sites are supported with structure and intention.
At Velocity, acquisition is about unlocking potential. When a site joins the organisation, its physicians are embedded within a broader clinical network and gain access to mentorship and cross-therapeutic training through programmes such as PIVOT. Standardised quality processes and centralised feasibility and regulatory support reduce the friction that often accompanies entry into new therapy areas. Best-performing sites share operational playbooks across countries, accelerating learning curves and reducing duplication of effort.
Sponsors see not a standalone site attempting to stretch into unfamiliar territory, but a site supported by the infrastructure of a broader organisation. Over time, what may have been a single-specialty site evolves into a multi-therapeutic research hub capable of competing for more complex and higher-value studies. When a site joins Velocity, it grows in both size and capability.
Collaboration models that reduce risk
Diversification is safer and faster when it is done as part of a coordinated network rather than in isolation. Sustainable expansion works best when supported by strategic Sponsor partnerships, early engagement in protocol design, and shared investment in training and infrastructure.
Velocity’s scale allows new therapeutic areas to be introduced across multiple sites in a coordinated way. This distributes risk, accelerates recruitment ramp-up, and creates greater predictability for sponsors. In turn, Sponsors gain speed, consistency, and quality, while sites benefit from stability, broader exposure, and sustainable growth.
Diversification as a resilience strategy
Europe’s clinical research landscape is complex. Regulatory frameworks vary significantly by country. Reimbursement systems differ. Sponsor pipelines shift in response to scientific and economic forces. Sites that depend heavily on a single therapeutic area are more vulnerable to these fluctuations.
Thoughtful diversification helps reduce that dependence. It protects against market cycles, attracts higher-value and more complex studies, and builds long-term strategic relationships with Sponsors. For Velocity, diversification supports geographic expansion and reinforces a resilient clinical services model grounded in performance, technology, and people. When done strategically, diversification is about building capability that endures.
